Liquid Biopsy Market Size, Share, In-Depth Analysis, Trends and Forecast 2026-2034
Liquid Biopsy Market 2026 Outlook:
Revolutionizing Cancer Diagnostics with Non-Invasive Precision Testing
The global oncology diagnostics landscape is undergoing a paradigm shift, with liquid biopsy emerging as one of the most transformative technologies in modern medicine. By enabling minimally invasive detection of tumour-derived components in blood and other body fluids, liquid biopsy is redefining how clinicians screen, diagnose, monitor, and treat cancer — without the complications and limitations of traditional tissue biopsy.
According to IMARC Group, the global Liquid Biopsy Market Size was valued at USD 2.60 Billion in 2025 and is projected to reach USD 7.61 Billion by 2034, growing at a CAGR of 12.31% during 2026–2034. This remarkable Liquid Biopsy Market Growth is underpinned by rising global cancer burden, rapid advances in next-generation sequencing (NGS), expanding precision oncology adoption, and surging demand for non-invasive early cancer detection solutions worldwide.
Liquid Biopsy Market Overview
Liquid biopsy is a minimally invasive diagnostic approach that analyses tumour-derived components circulating in body fluids — primarily blood, but also urine, saliva, and cerebrospinal fluid. It captures circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), extracellular vesicles (EVs), and tumour-educated platelets to support cancer screening, diagnosis, companion diagnostics, and treatment monitoring.
Applications span the entire oncology care pathway: early screening, therapy selection, minimal residual disease (MRD) detection, recurrence surveillance, and emerging uses in transplant rejection monitoring and prenatal testing. Clinical adoption continues to be supported by regulatory clearances, payer reimbursement, and inclusion in clinical guidelines globally.
Key liquid biopsy applications include:
• Early cancer screening and multi-cancer early detection (MCED)
• Companion diagnostics for targeted therapy selection
• Minimal residual disease (MRD) monitoring post-treatment
• Cancer recurrence surveillance
• Non-invasive prenatal testing (NIPT) and transplant rejection monitoring
Global Liquid Biopsy Market Size & Key Statistics
Below are the key Liquid Biopsy Market statistics drawn from IMARC Group's comprehensive market analysis:
|
Report Attribute |
Key Statistics |
|
Base Year |
2025 |
|
Historical Period |
2020–2025 |
|
Forecast Period |
2026–2034 |
|
Liquid Biopsy Market Size in 2025 |
USD 2.60 Billion |
|
Market Forecast in 2034 |
USD 7.61 Billion |
|
Market Growth Rate (2026–2034) |
12.31% CAGR |
|
Largest Region |
North America (38.6% share, 2025) |
|
Fastest Growing Region |
Asia-Pacific (~15.6% CAGR) |
|
Leading Product Segment |
Kits and Reagents (46.9%, 2025) |
|
Leading Biomarker Segment |
Circulating Tumor Cells (33.7%, 2025) |
Request for a Sample Report for Detailed Liquid Biopsy Market Share Evaluation: https://www.imarcgroup.com/liquid-biopsy-market/requestsample
Key Market Drivers & Liquid Biopsy Market Trends in 2026
Several powerful forces are shaping the Liquid Biopsy Market Trends and fuelling double-digit growth expectations across global oncology markets:
1. Rising Global Cancer Burden
GLOBOCAN 2022 estimated 19.97 million new cancer cases globally, with incidence projected to surpass 35 million by 2050. This structural rise directly expands the liquid biopsy demand base, making non-invasive, repeatable testing solutions more critical than ever for early detection and treatment monitoring at scale.
2. Precision Oncology and Companion Diagnostics Expansion
Over 100 FDA-approved targeted therapies now require molecular profiling prior to treatment, with approximately 40% accepting liquid biopsy as a validated alternative to tissue biopsy. This integration of liquid biopsy into therapy selection workflows is a primary driver of Liquid Biopsy Market Growth across clinical oncology settings.
3. NGS Cost Reduction and Technology Democratization
The cost of next-generation sequencing has declined significantly over consecutive years, making comprehensive genomic profiling economically viable across community oncology practices, not just major cancer centres. This democratization of NGS technology is accelerating liquid biopsy adoption globally.
4. Multi-Cancer Early Detection (MCED) Commercialization
MCED tests such as GRAIL's Galleri can detect 50+ cancer types from a single blood draw, representing a transformative opportunity in population-scale cancer screening. NHS England's 140,000-participant Galleri trial and ongoing commercial rollouts signal a major Liquid Biopsy Market Trend toward mainstream MCED deployment.
5. ctDNA-Based Minimal Residual Disease Monitoring
MRD monitoring post-surgery or chemotherapy is the fastest-growing clinical application in 2025. Natera's Signatera, Guardant Reveal, and NeoGenomics' RaDaR are competing for standard-of-care integration across adjuvant protocols, representing a USD 1.5–2 Billion opportunity by 2030.
6. AI and Machine Learning Integration
AI models are increasingly deployed in variant calling, fragmentomics, and methylation signature interpretation. Delfi Diagnostics' FirstLook lung cancer test exemplifies how AI-based fragmentomics is becoming a core clinical differentiator, enhancing both sensitivity and specificity of liquid biopsy results.
7. Expanding Payer Reimbursement Coverage
CMS National Coverage Determination now provides universal Medicare reimbursement for comprehensive genomic profiling in eligible advanced cancer patients in the United States. Expanding reimbursement — alongside FDA approvals of Guardant360 CDx, FoundationOne Liquid CDx, and Shield — is a critical catalyst for market expansion.
Key Market Segmentation
By Product and Service
Kits and Reagents – Largest Segment (46.9% Share, 2025): Kits and Reagents command the largest market share due to recurring per-test consumable economics. Every clinical liquid biopsy test consumes USD 300–800 in cfDNA extraction kits, NGS library preparation reagents, and enzymes — creating a revenue base that scales proportionally with test volume. QIAGEN, Thermo Fisher Scientific, and Roche lead this segment.
Platforms and Instruments (29.8%): This segment represents the capital-equipment layer, dominated by Illumina's NovaSeq and NextSeq sequencing systems. Rising NGS installations globally are expanding the instrument installed base, supporting long-term reagent pull-through revenue.
Services (23.3%): Services capture outsourced clinical testing volume handled by specialty reference laboratories such as Guardant Health, Natera, and NeoGenomics — reflecting the growing trend toward centralised, expert-led liquid biopsy testing.
By Circulating Biomarker
Circulating Tumor Cells (CTCs) – Largest (33.7%, 2025): CTCs dominate the biomarker segment, supported by established FDA-cleared platforms such as Menarini Silicon Biosystems' CellSearch for breast, prostate, and colorectal cancer monitoring — backed by over two decades of clinical validation.
Circulating Tumor DNA (ctDNA) – Fastest Growing (~14.2% CAGR): ctDNA holds a 28.6% share in 2025 and is growing the fastest, propelled by ctDNA-based MRD monitoring and comprehensive genomic profiling applications.
Extracellular Vesicles (21.4%): EVs are gaining traction in prostate, pancreatic, and lung cancer. ExoDx Prostate IntelliScore represents the first FDA breakthrough EV diagnostic in commercial deployment.
Others (16.3%): Includes tumour-educated platelets, circulating RNA, cell-free proteins, and methylation-based detection approaches.
By Cancer Type
Lung cancer leads the cancer type segment, reflecting the high prevalence of actionable mutations (EGFR, ALK, ROS1, KRAS) and the role of liquid biopsy in guiding targeted therapy selection and MRD monitoring. Breast cancer, colorectal cancer, prostate cancer, and liver cancer follow as significant segments.
By End User
Hospitals and Laboratories – Largest Segment: Hospitals and clinical laboratories account for the dominant end-user share, driven by high patient volumes, integrated oncology workflows, and the ability to embed liquid biopsy into routine cancer management protocols.
Academic and Research Centers: Academic institutions drive innovation in liquid biopsy through clinical trials, biomarker discovery, and validation studies — contributing to the expanding evidence base supporting regulatory clearances.
Regional Liquid Biopsy Market Analysis
|
Region |
Market Share (2025) |
Key Highlights |
|
North America – Largest |
38.6% |
US & Canada; FDA-cleared tests (Guardant360 CDx, FoundationOne Liquid CDx, Shield), CMS reimbursement, Guardant/GRAIL leadership, precision oncology ecosystem |
|
Europe |
26.9% |
Germany, France, UK leading; IVDR framework, NHS MCED rollout, EORTC adoption, Roche/QIAGEN manufacturing base |
|
Asia-Pacific – Fastest Growing |
22.4% |
China, Japan, India, South Korea, Australia; ~15.6% CAGR, NMPA approvals, Japan PMDA reimbursement, oncology infrastructure expansion |
|
Latin America |
6.5% |
Brazil, Mexico; Brazil largest LatAm healthcare market, private hospital adoption growing |
|
Middle East & Africa |
5.6% |
UAE, Saudi Arabia, South Africa; Saudi Vision 2030, precision medicine investment, growing oncology infrastructure |
North America commands the largest Liquid Biopsy Market Share at 38.6% of global revenue in 2025. The United States is the anchor market, supported by FDA approvals for Guardant360 CDx, FoundationOne Liquid CDx, Epi proColon, and GRAIL's Galleri, alongside CMS coverage for eligible advanced cancer patients.
Asia-Pacific at 22.4% in 2025 is the fastest-growing region, driven by China's NMPA approvals for domestic products from BGI Genomics, Burning Rock, and Genetron Health, Japan's Precision Medicine Initiative, and India's expanding oncology infrastructure under Ayushman Bharat.
Connect for Detailed Liquid Biopsy Market Share Segmentation Analysis – Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=5125&flag=C
Leading Players in the Liquid Biopsy Industry
The global liquid biopsy market features both diversified diagnostics giants and focused pure-play innovators. Key companies covered in the IMARC Group report include:
|
Company |
Key Platform / Offering |
Core Strength |
|
F. Hoffmann-La Roche Ltd |
AVENIO ctDNA Analysis Kits V2, FoundationOne Liquid CDx |
Pharma synergy, companion diagnostics, global reach |
|
Guardant Health Inc. |
Guardant360 CDx, Guardant Reveal, Shield |
ctDNA profiling, MRD, FDA-cleared MCED |
|
Illumina Inc. |
NovaSeq X, TruSight Oncology 500 ctDNA |
NGS platform dominance, 70%+ installed base |
|
Thermo Fisher Scientific Inc. |
MagMAX, Ion Torrent panels |
Targeted NGS, lab automation, global footprint |
|
Natera, Inc. |
Signatera, Constellation |
Personalised MRD monitoring, ctDNA |
|
Bio-Rad Laboratories, Inc. |
QX200 Droplet Digital PCR System& |
Bangla